drugset
drugset / Trial / NCT03772678

A Phase I Study to Evaluate LSALT Peptide

NCT03772678 ↗

Phase 0 Completed 52 enrolled Arch Biopartners Inc.
RandomizedSequentialQuadruple-blindBasic science

Summary

A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants

Timeline

Start
2019-06-27
Primary completion
2020-03-31
Completion
2020-03-31

Outcome

Met primary endpoint

release “In both groups, LSALT peptide met the primary endpoints of safety and tolerability.” archbiopartners.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject LSALT Peptide 0.01 mg Intravenous
Subject LSALT Peptide 0.1 mg Intravenous
Subject LSALT Peptide 0.3 mg Intravenous
Subject LSALT Peptide 0.5 mg Intravenous
Subject LSALT Peptide 1 mg Intravenous
Subject LSALT Peptide 2.5 mg Intravenous
Subject LSALT Peptide 5 mg Intravenous

Indications

No indication recorded.